A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT04594798
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
75 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Polatuzumab vedotin — DRUG
    IV 1.8 mg/kg per cycle
  • Rituximab — DRUG
    IV 375 mg/m2 per cycle
  • Cyclophosphamide — DRUG
    IV 400 mg/m2 per cycle
  • Doxorubicin — DRUG
    IV 25 mg/m2 per cycle
  • Prednisone — DRUG
    PO 40 mg/m2 per cycle

Study Details

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Key Dates

Start date
Sep 20, 2021
Status verified
Dec 2025
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
39 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Polatuzumab Vedotin and R-CHOP
    The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)

Primary Outcome Measure

Progression Free Survival [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of RochesterRochesterNew York14642-

Find similar trials in Rochester, NY

By research site
University of Rochester· Rochester, NY

Related Studies